药明康德(02359.HK)拟参与设立合资公司及成立合伙企业
格隆汇 3 月 8日丨药明康德(02359.HK)宣布,于2021年3月8日,公司全资子公司药明投资、MeadowSpring、晨壹及苏州民营资本订立组织章程细则,设立合资公司。根据组织章程细则,药明投资同意出资人民币4500万元,占合资公司注册资本的45%。
合资公司设立后,药明投资、MeadowSpring、嘉兴晨壹(晨壹的全资子公司)、苏州翼苏(苏州民营资本的全资子公司)及合资公司将订立合伙协议,成立合伙企业。根据合伙协议,药明投资(作为有限合伙人)将向合伙企业出资人民币4500万元,占合伙企业权益的44.55%。
合资公司计划在向中国证券投资基金业协会注册为私募基金管理人后,与合伙企业(作为基金普通合伙人)设立基金。基金为私募基金,专注于健康行业并购。基金将密切观察健康行业的发展趋势,把握大中华地区相关结构性成长机遇,重点投资健康行业的中后期标的。基金将进行的有关投资有助公司(其中包括)(i)拓宽生态圈、价值链及发展计划;及(ii)提升和加强于健康行业的地位。日后,倘未来投资计划可取且符合发展计划及主要业务,公司或会进一步对基金进行投资。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.